Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Account Payables
Amounts the company owes suppliers for goods and services received.
Surrozen, Inc.NASDAQ: SRZN
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 194.4% from a year ago
Account payables stood at $889K at the end of Q1 FY2026, up 194.4% from a year earlier and up 22.1% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.
Context
- Account payables amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +194.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 728K USD
- Year-over-year change
- +137.9%
- 4-year CAGR
- -28.1%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 728K | +137.9% |
| FY2024 | 2024-12-31 | 306K | -41.7% |
| FY2023 | 2023-12-31 | 525K | -20.2% |
| FY2022 | 2022-12-31 | 658K | -75.8% |
| FY2021 | 2021-12-31 | 2.72M | — |
Account Payables vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's Mar 2026 account payables of $889K is the 7th highest of the 8 companies compared; the peer median is $4.42M.
- Its year-over-year change of +194.4% is the 2nd highest of 8, against a peer median of +82.0%.
- Account payables amounts to 0.7% of total assets for SRZN, versus a peer median of 6.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $71.08M | +10.7% | +26.6% | 38.1% | |
| Mar 2026 | $4.73M | -17.6% | +236.3% | 4.9% | |
| Mar 2026 | $4.51M | +445.2% | — | 42.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.42M | +82.0% | +45.5% | 6.6% |
| Mar 2026 | $3.85M | +111.4% | -29.7% | 10.7% | |
| Mar 2026 | $2.5M | -43.9% | +38.7% | 0.9% | |
| Mar 2026 | $889K | +194.4% | +3.4% | 0.7% | |
| Mar 2026 | $793K | +177.3% | -30.9% | 0.4% | |
| Peer median (excluding SRZN) | $4.42M | +82.0% | +32.6% | 6.6% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33.09M | 24.69M | 36.04M | 34.57M | 89.25M |
| Short-term Investments | 68.76M | 51.15M | 0 | 0 | 0 |
| Net Receivables | 0 | 1.98M | 2.15M | 2.54M | 208K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 756K | 580K | 671K | 2.11M |
| Total Current Assets | 105.19M | 81.31M | 41.13M | 38.93M | 91.56M |
| Property, Plant & Equipment (Net) | 9.38M | 6.9M | 3.86M | 8.36M | 6.43M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 21.66M | 0 | 688K | 0 | 688K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 954K | 1.23M | 402K | 1.17M | 46K |
| Total Non-current Assets | 31.99M | 8.13M | 4.95M | 9.54M | 7.17M |
| Total Assets | 137.17M | 89.44M | 46.08M | 48.47M | 98.73M |
| Account Payables | 2.72M | 658K | 525K | 306K | 728K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 589K | 581K | 292K | 191K | 289K |
| Total Current Liabilities | 13.57M | 9.73M | 7.15M | 7.32M | 9.93M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 8.3M | 326K | 115K | 55.89M | 271.21M |
| Total Non-current Liabilities | 13.9M | 3.7M | 997K | 62.53M | 276.56M |
| Total Liabilities | 27.47M | 13.43M | 8.15M | 69.85M | 286.49M |
| Common Stock | 4K | 0 | 0 | 0 | 1K |
| Retained Earnings | (142.65M) | (178.65M) | (221.7M) | (285.26M) | (527.29M) |
| Accumulated OCI | (119K) | (241K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 109.7M | 76M | 37.94M | (21.38M) | (187.76M) |
| Total Debt | 7.79M | 5.6M | 3.38M | 8.47M | 6.64M |
| Net Debt | (25.3M) | (19.09M) | (32.66M) | (26.1M) | (82.61M) |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.